Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267176 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,020
- Enrollment target
NCT00267176 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,020 participants.
The verdict
NCT00267176, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,020 participants
- Enrollment target
Study Summary
This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.
Interventions
- DRUG lumiracoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2005-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00267176
The ClinicalTrials.gov registry entry for NCT00267176 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,020 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lumiracoxib is the first listed.
NCT00267176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00267176 about?
NCT00267176 is a clinical study titled "Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension". This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.
What is the current status of trial NCT00267176?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,020 participants. The study started on 2005-11.
What interventions are being tested in trial NCT00267176?
The interventions under investigation include: lumiracoxib (DRUG).
Who is sponsoring clinical trial NCT00267176?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.